anito-cel
anito-cel: developed by 1 company · 1 clinical trial tracked.
anito-cel evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect anito-cel to ACLX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could anito-cel → ACLX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Arcellx, Inc. (ACLX) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Primary endpoint: Assess safety profile, including any DLT and MTD (if applicable)
Interventionalopen30 targetStarted 2025-04Completion 2028-0413 sites · United StatesArcellx, Inc.
Frequently asked questions
Who is developing anito-cel?
anito-cel is being developed by Arcellx, Inc..
How many clinical trials involve anito-cel?
BioSniper tracks 1 clinical trial involving anito-cel.